PRX-07034

DB05993ExperimentalSmall molecule

Investigated for use/treatment in alzheimer's disease, obesity, and schizophrenia and schizoaffective disorders.

Mechanism: PRX-07034 is a novel, highly selective, small-molecule antagonist of a specific G-protein coupled receptor (GPCR) known as 5-HT6 being developed for the treatment of obesity, Alzheimer's disease and cognitive impairment associated with schizophrenia.
PRX-07034 has also been shown to enhance cognitive function in preclinical animal models of memory impairment through a dual mechanism of action.It has an effect on both the acetylcholine and glutamate neurotransmitter systems in the brain, which makes it a potentially complementary therapy to cholinesterase inhibitors, a class of drugs approved for the treatment of Alzheimer's disease.
Curator reviewed
Primary indication: Investigated for use/treatment in alzheimer's disease, obesity, and schizophrenia and schizoaffective disorders.Curator reviewed
Formula / weight: C₂₁H₂₉Cl₂N₃O₄S · 490.44 g/mol (avg)
Code names: PRX-07034

Resolves to

Compound

Structure

InChIKeyPILCQJJJAFRKHO-UHFFFAOYSA-NSMILESCl.COC1=C(OC)C(=CC(Cl)=C1)C(C)NC1=CC(=CC=C1S(C)(=O)=O)N1CCNCC1

Targets

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with PRX-07034, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.